The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.
In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.
Clinical trials are foundational to developing innovative, life-saving treatments and cures for patients. For developers of cell and gene therapy (CGTx) products, the path to clinical success is fraught with vast and complex challenges. The CGTx field is becoming more crowded, with increased clinical trial volume and an influx of less-experienced sponsors contributing to an increase in clinical holds in the category. Such challenges intensify the pressure to succeed in a fiercely competitive environment.
The cell and gene therapy space has undergone transformational change in the last few years, driven by the promise these modalities have demonstrated in addressing rare and intractable diseases. Achievements in the CAR-T therapy space – there are now six approved CAR-T treatments on the market – in conjunction with breakthroughs in gene therapy and viral vector drugs, have signaled a new era of innovation aimed at furthering cell and gene therapies within the greater healthcare landscape.
Precision will be at this year’s 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit, June 20-21, 2023, in Vienna, Austria. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the development for cell and gene therapies.
Connect with our Advanced Therapy experts!
You can register for the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit below:
Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges? Find out at Cell & Gene Day 2023, a free virtual event, streaming on demand HERE.
Precision is honored to be a co-host of this year’s ARM Cell & Gene Reception @ BIO, May 5, 2023, in Boston, MA. Attendees will enjoy extensive networking opportunities with the sector’s top decision makers including executives from leading companies located in the Boston area!
Connect with our Advanced Therapy experts!
Registration is complimentary – CLICK HERE to reserve your spot.
Precision will be at this year’s ASGCT, May 16-20, 2023, in Los Angeles, CA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the development for cell and gene therapies.
Connect with our Advanced Therapy experts!
You can register for ASGCT below:
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.